MCRB
insider transactionsSeres Therapeutics, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 90d
-474
0 buy · 474 sell
Net value · 90d
-$3.6K
$0 in · $3.6K out
Sentiment · 90d
Net selling
0% buying · 100% selling
Open-market trades · 90d
4
0 buy · 474 sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Sell·S
Director · 10b5-1
$2.0K
259 sh · $7.53
Own -2%
-
Sell·S
Chief Scientific Officer and … · 10b5-1
$580
77 sh · $7.53
Own -1%
-
Sell·S
EVP and Chief Legal Officer · 10b5-1
$595
79 sh · $7.53
Own -1%
-
Sell·S
Chief Operating Officer, EVP
$444
59 sh · $7.53
Own -1%
-
Exercise·M
Director · 10b5-1
$0
331 sh
Own +17%
-
Exercise·M
Director · 10b5-1
$0
391 sh
Own +50%
-
Exercise·M
Director · 10b5-1
—
722 sh
Own +6%
-
Exercise·M
Chief Scientific Officer and … · 10b5-1
$0
97 sh
Own +17%
-
Exercise·M
Chief Scientific Officer and … · 10b5-1
$0
141 sh
Own +50%
-
Exercise·M
Chief Scientific Officer and … · 10b5-1
—
238 sh
Own +3%
-
Exercise·M
EVP and Chief Legal Officer · 10b5-1
$0
111 sh
Own +17%
-
Exercise·M
EVP and Chief Legal Officer · 10b5-1
$0
133 sh
Own +50%
-
Exercise·M
EVP and Chief Legal Officer · 10b5-1
—
244 sh
Own +3%
-
Exercise·M
Chief Operating Officer, EVP
$0
91 sh
Own +17%
-
Exercise·M
Chief Operating Officer, EVP
$0
89 sh
Own +49%
-
Exercise·M
Chief Operating Officer, EVP
—
180 sh
Own +2%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| May 18, 2026 | Eric D. Shaff 10b5-1 | Sell S | 259 | $2.0K |
| May 18, 2026 | Matthew R Henn 10b5-1 | Sell S | 77 | $580 |
| May 18, 2026 | Thomas Desrosier 10b5-1 | Sell S | 79 | $595 |
| May 18, 2026 | Kelly Brady | Sell S | 59 | $444 |
| May 15, 2026 | Eric D. Shaff 10b5-1 | Exercise M | 331 | $0 |
| May 15, 2026 | Eric D. Shaff 10b5-1 | Exercise M | 391 | $0 |
| May 15, 2026 | Eric D. Shaff 10b5-1 | Exercise M | 722 | — |
| May 15, 2026 | Matthew R Henn 10b5-1 | Exercise M | 97 | $0 |
| May 15, 2026 | Matthew R Henn 10b5-1 | Exercise M | 141 | $0 |
| May 15, 2026 | Matthew R Henn 10b5-1 | Exercise M | 238 | — |
| May 15, 2026 | Thomas Desrosier 10b5-1 | Exercise M | 111 | $0 |
| May 15, 2026 | Thomas Desrosier 10b5-1 | Exercise M | 133 | $0 |
| May 15, 2026 | Thomas Desrosier 10b5-1 | Exercise M | 244 | — |
| May 15, 2026 | Kelly Brady | Exercise M | 91 | $0 |
| May 15, 2026 | Kelly Brady | Exercise M | 89 | $0 |
| May 15, 2026 | Kelly Brady | Exercise M | 180 | — |
About MCRB insider trading
This page tracks insider transactions for Seres Therapeutics, Inc. (MCRB) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.